Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.
D000367:Age Factors; D000906:Antibodies / Q000032:analysis; D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003120:Colorado; D003168:Complement Fixation Tests; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006760:Hospitalization; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007223:Infant; D008297:Male; D008458:Measles Vaccine; D009976:Orthomyxoviridae Infections / Q000453:epidemiology / Q000517:prevention & control; D018184:Paramyxoviridae Infections / Q000453:epidemiology; D011159:Population Surveillance; D012136:Respiratory Syncytial Viruses / Q000276:immunology* / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000517:prevention & control; D018108:Respirovirus / Q000276:immunology*; D012621:Seasons; D014611:Vaccination; D014765:Viral Vaccines
D000906:Antibodies; D008458:Measles Vaccine; D014765:Viral Vaccines; D003165:Complement System Proteins